Salicin

Spécifications

138-52-3Numéro CAS

205-331-6Numéro CE

(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triolNom IUPAC

C13H18O7Formule chimique

286.28 g/molMasse molaire

salicin; 138-52-3; Salicoside; D-(-)-Salicin; Salicyl alcohol glucoside; D(-)-Salicin; 2-(Hydroxymethyl)phenyl beta-D-glucopyranoside; Saligenin beta-D-glucopyranoside; 2-(Hydroxymethyl)phenyl-beta-d-glucopyranoside; Salicinum; o-(Hydroxymethyl)phenyl beta-D-glucopyranoside; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol; DTXSID10883326; NSC-5751; 4649620TBZ; CHEBI:17814; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)oxane-3,4,5-triol; RefChem:884384; DTXCID901022864; Salicine; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; D-Salicin; Saligenin-beta-D-glucopyranoside; MFCD00006590; alpha-Hydroxy-o-tolyl beta-D-glucopyranoside; Benzyl alcohol, o-hydroxy-, o-glucoside; AI3-19099; SPECTRUM1502255; B-D-Glucopyranoside, 2-(hydroxymethyl)phenyl; D-()-Salicin; SDCCGMLS-0066698.P001; NCGC00142605-01; NSC 5751; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]tetrahydropyran-3,4,5-triol; (2S,4S,5S,3R,6R)-6-(hydroxymethyl)-2-[2-(hydroxymethyl)phenoxy]-2H-3,4,5,6-tet rahydropyran-3,4,5-triol; SMR000112301; Salicin [USP]; SR-05000001594; Salicin (6CI,8CI); EINECS 205-331-6; delta-Salicin; UNII-4649620TBZ; Salicin CRS; (2R,3S,4S,5R,6S)-2-(Hydroxymethyl)-6-(2-(hydroxymethyl)-phenoxy)tetrahydro-2H-pyran-3,4,5-triol; SA0; D-Salicin, natural; Salicin (Standard); Saligenin glucoside;; Spectrum_001230; 2-(Hydroxymethyl)phenyl-.beta.-d-glucopyranoside; SALICIN [MI]; SALICINUM [HPUS]; 2-(Hydroxymethyl)phenyl b-D-glucopyranoside; Spectrum2_000756; Spectrum3_000948; Spectrum4_001058; Spectrum5_000971; D-()-Salicin;Salicoside; bmse000315; D-SALICIN [USP-RS]; SCHEMBL24936; KBioGR_001356; KBioSS_001710; Saligenin-b-D-glucopyranoside; MLS000563050; MLS001306490; DivK1c_000030; S0625_SIGMA; SPBio_000772; CHEMBL462997; MEGxp0_000685; orb1310611; orb3140646; Salicin (Salicoside, Salicine); SCHEMBL29891411; ACon1_000373; GTPL12454; HMS500B12; HY-N0149R; KBio1_000030; KBio2_001710; KBio2_004278; KBio2_006846; KBio3_002016; NINDS_000030; GLXC-13826; HMS1921P08; HMS2092F14; HMS2268J11; HMS3884B15; Pharmakon1600-01502255; HY-N0149; MSK40324; Saligenin beta-delta-glucopyranoside; Saligenin-beta-delta-glucopyranoside; D-(-)-Salicin, analytical standard; CCG-40332; NSC758201; s2351; SBB012498; ZINC03847505; AKOS004907439; AC-8042; CS-8027; D-(-)-Salicin, >=99% (GC); EBC-378119; MS01266; NSC-758201; IDI1_000030; NCGC00142605-02; NCGC00142605-04; ST069327; SY038043; SALICYL ALCOHOL GLUCOSIDE [WHO-DD]; SBI-0051746.P002; 2(hydroxymethyl)phenyl-beta-D-glucopyranoside; NS00015239; S0003; S0048; SW219123-1; T0443; |A-D-Glucopyranoside, 2-(hydroxymethyl)phenyl; C01451; S-1498; 2-(Hydroxymethyl)-phenyl-beta-D-glucopyranoside; 2-(hydroxymethyl)phenyl-O-beta-D-glucopyranoside; AB00052296_07; F212842; Q419173; SR-05000001594-1; SR-05000001594-2; BRD-K64614248-001-02-4; BRD-K64614248-001-06-5; BRD-K64614248-001-11-5; BRD-K64614248-001-12-3; EAD32BE1-198E-432C-9F44-DC0DC9A3305B; Salicin, European Pharmacopoeia (EP) Reference Standard; D-Salicin, United States Pharmacopeia (USP) Reference StandardSynonymes